Hearing Protection, Restoration, and Regeneration: An Overview of Emerging Therapeutics for Inner Ear and Central Hearing Disorders
To provide an overview of biotechnology and pharmaceutical companies active in the field of inner ear and central hearing disorders and their therapeutic approaches. Scientific and grey literature was searched using broad search terms to identify companies and their hearing-related therapeutic appro...
Uložené v:
| Vydané v: | Otology & neurotology Ročník 40; číslo 5; s. 559 |
|---|---|
| Hlavní autori: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.06.2019
|
| Predmet: | |
| ISSN: | 1537-4505, 1537-4505 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | To provide an overview of biotechnology and pharmaceutical companies active in the field of inner ear and central hearing disorders and their therapeutic approaches.
Scientific and grey literature was searched using broad search terms to identify companies and their hearing-related therapeutic approaches. For each approach its lead indication, product, therapeutic modality, target, mechanism of action and current phase of clinical development was collated.
A total of 43 biotechnology and pharmaceutical companies have been identified that are developing therapeutics for inner ear and central hearing disorders. Their therapeutics include drug-, cell- and gene-based approaches to prevent hearing loss or its progression, restore hearing, and regenerate the inner ear. Their therapeutic targets and specific mechanisms of action are wide-ranging, reflecting the complexity of the hearing pathways and the diversity of mechanisms underlying inner ear disorders. While none of the novel products under investigation have yet made it to the clinical market, and a large proportion are still at preclinical phase, many therapeutics have already entered clinical testing with more expected to do so in the next few years.
A wide range of novel therapeutics targeting different hearing, balance and tinnitus pathways, and patient populations are approaching the clinical domain. It is important that clinicians involved in the care of patients with hearing loss prepare for what may become a radically different approach to the management of hearing disorders, and develop a true understanding of the new therapies' mechanisms of action, applications, and indications. |
|---|---|
| AbstractList | To provide an overview of biotechnology and pharmaceutical companies active in the field of inner ear and central hearing disorders and their therapeutic approaches.
Scientific and grey literature was searched using broad search terms to identify companies and their hearing-related therapeutic approaches. For each approach its lead indication, product, therapeutic modality, target, mechanism of action and current phase of clinical development was collated.
A total of 43 biotechnology and pharmaceutical companies have been identified that are developing therapeutics for inner ear and central hearing disorders. Their therapeutics include drug-, cell- and gene-based approaches to prevent hearing loss or its progression, restore hearing, and regenerate the inner ear. Their therapeutic targets and specific mechanisms of action are wide-ranging, reflecting the complexity of the hearing pathways and the diversity of mechanisms underlying inner ear disorders. While none of the novel products under investigation have yet made it to the clinical market, and a large proportion are still at preclinical phase, many therapeutics have already entered clinical testing with more expected to do so in the next few years.
A wide range of novel therapeutics targeting different hearing, balance and tinnitus pathways, and patient populations are approaching the clinical domain. It is important that clinicians involved in the care of patients with hearing loss prepare for what may become a radically different approach to the management of hearing disorders, and develop a true understanding of the new therapies' mechanisms of action, applications, and indications. To provide an overview of biotechnology and pharmaceutical companies active in the field of inner ear and central hearing disorders and their therapeutic approaches.OBJECTIVETo provide an overview of biotechnology and pharmaceutical companies active in the field of inner ear and central hearing disorders and their therapeutic approaches.Scientific and grey literature was searched using broad search terms to identify companies and their hearing-related therapeutic approaches. For each approach its lead indication, product, therapeutic modality, target, mechanism of action and current phase of clinical development was collated.METHODSScientific and grey literature was searched using broad search terms to identify companies and their hearing-related therapeutic approaches. For each approach its lead indication, product, therapeutic modality, target, mechanism of action and current phase of clinical development was collated.A total of 43 biotechnology and pharmaceutical companies have been identified that are developing therapeutics for inner ear and central hearing disorders. Their therapeutics include drug-, cell- and gene-based approaches to prevent hearing loss or its progression, restore hearing, and regenerate the inner ear. Their therapeutic targets and specific mechanisms of action are wide-ranging, reflecting the complexity of the hearing pathways and the diversity of mechanisms underlying inner ear disorders. While none of the novel products under investigation have yet made it to the clinical market, and a large proportion are still at preclinical phase, many therapeutics have already entered clinical testing with more expected to do so in the next few years.RESULTSA total of 43 biotechnology and pharmaceutical companies have been identified that are developing therapeutics for inner ear and central hearing disorders. Their therapeutics include drug-, cell- and gene-based approaches to prevent hearing loss or its progression, restore hearing, and regenerate the inner ear. Their therapeutic targets and specific mechanisms of action are wide-ranging, reflecting the complexity of the hearing pathways and the diversity of mechanisms underlying inner ear disorders. While none of the novel products under investigation have yet made it to the clinical market, and a large proportion are still at preclinical phase, many therapeutics have already entered clinical testing with more expected to do so in the next few years.A wide range of novel therapeutics targeting different hearing, balance and tinnitus pathways, and patient populations are approaching the clinical domain. It is important that clinicians involved in the care of patients with hearing loss prepare for what may become a radically different approach to the management of hearing disorders, and develop a true understanding of the new therapies' mechanisms of action, applications, and indications.CONCLUSIONA wide range of novel therapeutics targeting different hearing, balance and tinnitus pathways, and patient populations are approaching the clinical domain. It is important that clinicians involved in the care of patients with hearing loss prepare for what may become a radically different approach to the management of hearing disorders, and develop a true understanding of the new therapies' mechanisms of action, applications, and indications. |
| Author | Holme, Ralph Schilder, Anne G M Warnecke, Athanasia Gomes-Santos, Carina S Lustig, Lawrence Staecker, Hinrich Blackshaw, Helen Lenarz, Thomas Safieddine, Saaid Su, Matthew P |
| Author_xml | – sequence: 1 givenname: Anne G M surname: Schilder fullname: Schilder, Anne G M organization: National Institute of Health Research University College London Hospitals Biomedical Research Centre, London, UK – sequence: 2 givenname: Matthew P surname: Su fullname: Su, Matthew P organization: National Institute of Health Research University College London Hospitals Biomedical Research Centre, London, UK – sequence: 3 givenname: Helen surname: Blackshaw fullname: Blackshaw, Helen organization: National Institute of Health Research University College London Hospitals Biomedical Research Centre, London, UK – sequence: 4 givenname: Lawrence surname: Lustig fullname: Lustig, Lawrence organization: Department of Otolaryngology Head and Neck Surgery, Columbia University, New York – sequence: 5 givenname: Hinrich surname: Staecker fullname: Staecker, Hinrich organization: Department of Otolaryngology Head and Neck Surgery, University of Kansas Medical Center, Kansas City, Kansas – sequence: 6 givenname: Thomas surname: Lenarz fullname: Lenarz, Thomas organization: Cluster of Excellence "Hearing for all", German Research Foundation, Germany – sequence: 7 givenname: Saaid surname: Safieddine fullname: Safieddine, Saaid organization: Sorbonne University, Pierre and Marie Curie University Paris, Paris, France – sequence: 8 givenname: Carina S surname: Gomes-Santos fullname: Gomes-Santos, Carina S organization: Action on Hearing Loss, London, UK – sequence: 9 givenname: Ralph surname: Holme fullname: Holme, Ralph organization: Action on Hearing Loss, London, UK – sequence: 10 givenname: Athanasia surname: Warnecke fullname: Warnecke, Athanasia organization: Cluster of Excellence "Hearing for all", German Research Foundation, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31083073$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUMtOwzAQtFARpYU_QMhHDqT4ETsxt6oUWqmoCJVzZMdOCUrsYidFnPlxAm2l7mV3R7Mzmh2AnnXWAHCF0Qgjkdw9j5cjdFQEi_gEnGNGkyhmiPWO5j4YhPCBEE4oS85An2KUUpTQc_AzM9KXdg1fvGtM3pTO3sJXExrn5W6RVnfA2lizQ-7h2MLl1vhtab6gK-C0Nn79J7F67ygb0zZlHmDhPJzb7ghOpf8XmRjbeFnBg-NDGZzXxocLcFrIKpjLfR-Ct8fpajKLFsun-WS8iPI4xXEkkoIqTQRmmOexLqhWKUdKCdbF4RopTlKhBS40T7WMiWRJTLgqlEBScYbJENzsdDfefbZdxqwuQ26qSlrj2pARQrFIBeGio17vqa2qjc42vqyl_84OjyO_ze9y5A |
| CitedBy_id | crossref_primary_10_1121_10_0013706 crossref_primary_10_1097_MAO_0000000000003069 crossref_primary_10_1111_joa_13459 crossref_primary_10_1016_j_drudis_2021_11_009 crossref_primary_10_3390_biom11121896 crossref_primary_10_1056_NEJMcp2306778 crossref_primary_10_1089_ars_2021_0166 crossref_primary_10_1080_14992027_2024_2387291 crossref_primary_10_1016_j_otc_2021_05_003 crossref_primary_10_1016_j_arr_2020_101042 crossref_primary_10_1038_s41598_023_45024_3 crossref_primary_10_1136_thoraxjnl_2019_214177 crossref_primary_10_3389_fncel_2021_602897 crossref_primary_10_3389_fnagi_2021_730758 crossref_primary_10_3390_bioengineering11050425 crossref_primary_10_1016_j_envres_2023_117115 crossref_primary_10_1016_j_joto_2021_05_001 crossref_primary_10_1080_14992027_2024_2389465 crossref_primary_10_1016_j_cophys_2020_07_004 crossref_primary_10_1038_s41467_024_45784_0 crossref_primary_10_3390_brainsci10100756 crossref_primary_10_3390_ijms242216545 crossref_primary_10_1121_10_0011739 crossref_primary_10_1080_10717544_2021_1943059 crossref_primary_10_1146_annurev_genom_121321_094136 crossref_primary_10_1016_j_heares_2023_108783 crossref_primary_10_1016_j_ijpharm_2020_120038 crossref_primary_10_1080_00016489_2024_2344807 crossref_primary_10_1016_j_otc_2021_08_008 crossref_primary_10_1121_10_0017002 crossref_primary_10_3389_fncel_2019_00551 crossref_primary_10_3390_jcm9072309 crossref_primary_10_1016_j_heares_2022_108523 crossref_primary_10_3389_fnagi_2022_814528 crossref_primary_10_1097_MAO_0000000000002744 crossref_primary_10_1002_adbi_202300613 crossref_primary_10_3390_ijms22084189 crossref_primary_10_3390_biom12040498 crossref_primary_10_1121_10_0014418 crossref_primary_10_1007_s00439_021_02359_z crossref_primary_10_3390_ijms221910849 crossref_primary_10_3389_fneur_2025_1598789 crossref_primary_10_1097_01_HJ_0000911296_83475_19 crossref_primary_10_3389_fnagi_2021_647285 crossref_primary_10_1016_j_heares_2019_07_003 crossref_primary_10_1002_advs_202500556 crossref_primary_10_1016_j_heares_2022_108637 crossref_primary_10_1002_stem_3346 crossref_primary_10_1080_13543784_2023_2253141 crossref_primary_10_3389_fncel_2021_791573 crossref_primary_10_3389_fnins_2023_1296458 crossref_primary_10_1097_AUD_0000000000001522 crossref_primary_10_3390_ijms26083709 crossref_primary_10_1016_j_heares_2021_108209 crossref_primary_10_1121_1_5132706 crossref_primary_10_1016_j_otc_2021_04_001 crossref_primary_10_3389_fnins_2023_1202429 crossref_primary_10_3389_fbioe_2022_776890 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/MAO.0000000000002194 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1537-4505 |
| ExternalDocumentID | 31083073 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: Department of Health grantid: NIHR-RP-011-045 |
| GroupedDBID | --- .-D .GJ .Z2 0R~ 123 1J1 4Q1 4Q2 4Q3 53G 5VS AAAAV AAHPQ AAIQE AAMTA AARTV AASCR AASOK AAWTL AAYEP ABASU ABBUW ABDIG ABJNI ABPXF ABVCZ ABXVJ ABZAD ABZZY ACBNA ACCJW ACDDN ACEWG ACGFS ACILI ACNWC ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFBFQ AFDTB AFUWQ AGINI AHQNM AHRYX AHVBC AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BQLVK BS7 C45 CGR CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD EX3 F2K F2L F2M F2N FCALG FL- FW0 GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ IPNFZ JF9 JG8 JK3 JK8 K8S KD2 KMI L-C L7B N4W N9A NPM N~M O9- OAG OAH OCUKA ODA OHT OL1 OLV OLZ OPUJH ORVUJ OUVQU OVD OVDNE OWU OWV OWX OWY OWZ OXXIT R58 RIG RLZ S4R S4S T8P TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W XXN XYM ZFV ZGI ZZMQN 7X8 ADKSD |
| ID | FETCH-LOGICAL-c4814-97f3bd291516c4df3db860bb953106d0b6289d91fd68da42a57426bfb90ab6512 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 68 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000480679800015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1537-4505 |
| IngestDate | Sun Sep 28 12:05:16 EDT 2025 Sat May 31 02:12:30 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4814-97f3bd291516c4df3db860bb953106d0b6289d91fd68da42a57426bfb90ab6512 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://hal.science/hal-02365389 |
| PMID | 31083073 |
| PQID | 2231989269 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2231989269 pubmed_primary_31083073 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-June |
| PublicationDateYYYYMMDD | 2019-06-01 |
| PublicationDate_xml | – month: 06 year: 2019 text: 2019-June |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Otology & neurotology |
| PublicationTitleAlternate | Otol Neurotol |
| PublicationYear | 2019 |
| SSID | ssj0017357 |
| Score | 2.5088673 |
| SecondaryResourceType | review_article |
| Snippet | To provide an overview of biotechnology and pharmaceutical companies active in the field of inner ear and central hearing disorders and their therapeutic... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 559 |
| SubjectTerms | Biotechnology - methods Biotechnology - trends Drug Industry - methods Drug Industry - trends Ear, Inner Hearing Aids - trends Hearing Loss - therapy Humans Otolaryngology - methods Otolaryngology - trends Regenerative Medicine - methods Regenerative Medicine - trends |
| Title | Hearing Protection, Restoration, and Regeneration: An Overview of Emerging Therapeutics for Inner Ear and Central Hearing Disorders |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31083073 https://www.proquest.com/docview/2231989269 |
| Volume | 40 |
| WOSCitedRecordID | wos000480679800015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7qinjx_VhfRPBoMNumaeNFFtllPewDWWFvJWkS8dKuW11_gH_cSZuyJ0Gwh0IDbUMyM_kyM_kGoRvLjAE9siQKpSLMUE1UlGhipdSGcR2FVFbFJuLRKJnNxMQ73EqfVtnYxMpQ6yJzPvI7WMZcek_AxcP8nbiqUS666ktorKNWCFDGSXU8W0UR4rBi-gSldtzeNGqOzon4btgd19SF_gLFZb-DzGqx6e_-t5t7aMfDTNyt5WIfrZn8AG0NfSD9EH0PQMJh1cKTmqcBZucWP1dVZmT9IHMNDa8VK7VrucfdHI-XzrSYL1xY7NxZrsIRnq6OcJUYMDB-cuW8cE8uqo94_zFu_tjwfZZH6KXfmz4OiK_HQDKWdBgRsQ2VDgSABJ4xbUOtEk6VEqDHlGuqOOzetOhYzRMtWSAj2HdzZZWgUnFAFsdoIy9yc4pwRgPtqNXcsV5mtJUZwIyAZiHLDGXWttF1M7wpyLsLYsjcFJ9luhrgNjqp5yid18QcKXQjcTbr7A9vn6NtwD6izvq6QC0L2m4u0Wa2_HgrF1eVIMF9NBn-AB7s0w8 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hearing+Protection%2C+Restoration%2C+and+Regeneration%3A+An+Overview+of+Emerging+Therapeutics+for+Inner+Ear+and+Central+Hearing+Disorders&rft.jtitle=Otology+%26+neurotology&rft.au=Schilder%2C+Anne+G+M&rft.au=Su%2C+Matthew+P&rft.au=Blackshaw%2C+Helen&rft.au=Lustig%2C+Lawrence&rft.date=2019-06-01&rft.eissn=1537-4505&rft.volume=40&rft.issue=5&rft.spage=559&rft_id=info:doi/10.1097%2FMAO.0000000000002194&rft_id=info%3Apmid%2F31083073&rft_id=info%3Apmid%2F31083073&rft.externalDocID=31083073 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-4505&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-4505&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-4505&client=summon |